Development of a diagnostic method for pancreatic cancer using 13C glucose

Development of a new diagnostic method for pancreatic cancer using 13C-labeled glucose-derived metabolites: a single-arm, exploratory clinical study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051210205

Enrollment

Registered

2022-03-25

Start date

2023-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer, benign pancreatic diseases, or other gastroenterological cancers Pancreatic cancer

Interventions

Oral administration of 13C-labeled glucose

13C-labeled glucose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age over 20, under 80 2. Diagnosed patients of pancreatic cancer, benigh pancreatic disease or other gastroenterological cancer 3. Patients who have given their free and written consent to participate in this clinical research.

Exclusion criteria

Exclusion criteria: 1. ECOG-PS 4, or patients who have difficulty urinating or collecting urine on their own 2. Patients deemed inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
Level of 13C glucose-derived metabolites present in urine after 13C glucose administration	—

Secondary

Measure	Time frame
1. Presence of 13C glucose-derived metabolites in urine after administration of 13C glucose 2. 13C glucose-derived metabolites (unknown metabolites) 3. Metabolites containing 13C 4. Occurrence of disease or symptom	—

Contacts

Public ContactTakashi Kobayashi

Kobe University Hospital

kobatak@med.kobe-u.ac.jp+81-78-382-6305

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026